Carey K. Anders
Elite in Brain Tumor

Dr. Carey K. Anders

Oncology
Duke Health
Duke Cancer Center Brain Tumor Clinic
20 Duke Medicine Cir, 
Durham, NC 
Accepting New Patients
Offers Telehealth

Elite in Brain Tumor
Duke Health
Duke Cancer Center Brain Tumor Clinic
20 Duke Medicine Cir, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

My clinical practice if focused on the care of patients with breast cancer, particularly those diagnosed at a younger age and those with recurrence in the central nervous system. I am committed to the care of patients with breast cancer brain metastases, and I am honored to serve as the Medical Director of the Brain and Spine Metastases Program in the Duke Cancer Center. In this role, our multidisciplinary team provides well-coordinated care for patients with breast cancer and other solid tumor types that have metastasized to the central nervous system. In addition, I enjoy helping young women diagnosed with breast cancer navigate their treatment decisions to ensure both excellent medical care and attention to individual challenges, such as future fertility, sequelae of treatment on longer-term health, and impact on current and future relationships. When not working, I enjoy running, reading, and traveling with my family.

Dr. Anders is rated as an Elite provider by MediFind in the treatment of Brain Tumor. Her top areas of expertise are Breast Cancer, Brain Tumor, Triple-Negative Breast Cancer, and Metastatic Brain Tumor.

Her clinical research consists of co-authoring 158 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 69 articles and participated in 5 clinical trials in the study of Brain Tumor.

Specialties
Oncology
Licenses
Internal Medicine in NC
Fellowships
Oncology, Duke University
Hospital Affiliations
Duke Regional Hospital
Duke University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Ambetter
  • EPO
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Duke Cancer Center Brain Tumor Clinic
20 Duke Medicine Cir, Durham, NC 27710
Call: 919-684-5301

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


18 Clinical Trials

A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker
A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker
Enrollment Status: Completed
Publish Date: September 26, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, Cisplatin
Study Phase: Phase 2
AURORA US: Prospective Biospecimen Repository in Metastatic Breast Cancer
AURORA US: Prospective Biospecimen Repository in Metastatic Breast Cancer
Enrollment Status: Suspended
Publish Date: September 03, 2025
Intervention Type: Procedure, Other
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2025
Intervention Type: Other
Study Phase: Not Applicable
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Veliparib
Study Phase: Phase 2
A Phase II Trial of HKI-272 (Neratinib), Neratinib and Capecitabine, and Ado-Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases
A Phase II Trial of HKI-272 (Neratinib), Neratinib and Capecitabine, and Ado-Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: March 04, 2025
Intervention Type: Drug, Procedure
Study Drugs: HKI-272, Capecitabine, Ado-Trastuzumab Emtansine
Study Phase: Phase 2
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Enrollment Status: Terminated
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: ELU001
Study Phase: Phase 1/Phase 2
A Non-randomized, Non-comparative, Open-label, Window Trial of Entinostat Given With or Without Exemestane in Patients With Newly Diagnosed, Stage I-IIIC, Hormone Receptor - Positive (HR+) or Triple Negative Breast Cancer (TNBC)
A Non-randomized, Non-comparative, Open-label, Window Trial of Entinostat Given With or Without Exemestane in Patients With Newly Diagnosed, Stage I-IIIC, Hormone Receptor - Positive (HR+) or Triple Negative Breast Cancer (TNBC)
Enrollment Status: Terminated
Publish Date: March 25, 2024
Intervention Type: Drug
Study Phase: Early Phase 1
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
Phase II Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
Phase II Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
Enrollment Status: Completed
Publish Date: May 22, 2023
Intervention Type: Drug
Study Drugs: Pembrolizumab, Cyclophosphamide
Study Phase: Phase 2
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 Alone and in Combination With Palbociclib in Women With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 Alone and in Combination With Palbociclib in Women With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Enrollment Status: Completed
Publish Date: December 15, 2022
Intervention Type: Drug
Study Drugs: G1T48, Palbociclib
Study Phase: Phase 1
A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Enrollment Status: Completed
Publish Date: April 15, 2022
Intervention Type: Procedure, Drug
Study Phase: Phase 2
LCCC 1642: Plasma Circulating Tumor DNA (ctDNA) Analyses in ER+ Metastatic Breast Cancer
LCCC 1642: Plasma Circulating Tumor DNA (ctDNA) Analyses in ER+ Metastatic Breast Cancer
Enrollment Status: Withdrawn
Publish Date: May 21, 2021
Intervention Type: Other
A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma
A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma
Enrollment Status: Completed
Publish Date: December 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
LCCC 1410: Impact of Physical Activity on Biomarker of Aging and Body Composition Among Breast Cancer Survivors Age 65 and Older
LCCC 1410: Impact of Physical Activity on Biomarker of Aging and Body Composition Among Breast Cancer Survivors Age 65 and Older
Enrollment Status: Completed
Publish Date: April 30, 2020
Intervention Type: Behavioral
Study Phase: Not Applicable
A Phase II Study Evaluating The Efficacy And Tolerability Of Everolimus (RAD001) In Combination With Trastuzumab And Vinorelbine In The Treatment Of Progressive HER2-Positive Breast Cancer Brain Metastases
A Phase II Study Evaluating The Efficacy And Tolerability Of Everolimus (RAD001) In Combination With Trastuzumab And Vinorelbine In The Treatment Of Progressive HER2-Positive Breast Cancer Brain Metastases
Enrollment Status: Completed
Publish Date: December 17, 2018
Intervention Type: Drug
Study Phase: Phase 2
FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions
FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions
Enrollment Status: Withdrawn
Publish Date: November 14, 2018
Intervention Type: Drug
Impact of a Physical Activity Program on Biomarkers of Aging During Adjuvant or Neoadjuvant Chemotherapy for Breast Cancer
Impact of a Physical Activity Program on Biomarkers of Aging During Adjuvant or Neoadjuvant Chemotherapy for Breast Cancer
Enrollment Status: Completed
Publish Date: June 06, 2018
Intervention Type: Behavioral
A Randomized, Wait-list Controlled Clinical Trial: the Effect of a Physical Activity Program on Fatigue After Potentially Curative Chemotherapy Among Cancer Survivors Age 65 or Older -- PACT (Physical Activity After Chemotherapy)
A Randomized, Wait-list Controlled Clinical Trial: the Effect of a Physical Activity Program on Fatigue After Potentially Curative Chemotherapy Among Cancer Survivors Age 65 or Older -- PACT (Physical Activity After Chemotherapy)
Enrollment Status: Completed
Publish Date: September 12, 2017
Intervention Type: Behavioral
Study Phase: Not Applicable
View 17 Less Clinical Trials

158 Total Publications

A HER3-targeting antibody-drug conjugate for leptomeningeal metastasis.
A HER3-targeting antibody-drug conjugate for leptomeningeal metastasis.
Journal: Nature medicine
Published: July 31, 2025
View All 158 Publications
Similar Doctors
Henry S. Friedman
Elite in Brain Tumor
Dr. Henry S. Friedman
Neurosurgery | Hematology | Oncology
Elite in Brain Tumor
Dr. Henry S. Friedman
Neurosurgery | Hematology | Oncology

Duke Cancer Center Brain Tumor Clinic

20 Duke Medicine Cir, 
Durham, NC 
 (0.1 miles away)
919-684-5301
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

I am an academic adult and pediatric neuro-oncologist who helps lead The Preston Robert Tisch Brain Tumor Center at Duke. I am the author of more than 500 peer-reviewed articles, reviews, and book chapters, and I have presented extensively at both international and national meetings. I am a committed educator who is a member of the executive and super-executive committees of the Duke University School of Medicine, which are responsible for the recruitment, screening and selection of medical students. I have reviewed grants for the National Institutes of Health for over 15 years, in a spectrum of different study sections. I am the senior editor of CNS Oncology and a reviewer for over 25 academic journals. I serve on the advisory board of a number of organizations, including Voices Against Brain Cancer, the Tug McGraw Foundation, Pinnacle Care, the Pediatric Brain Tumor Foundation, the National Children’s Cancer Society, and the American Brain Tumor Association. Dr. Friedman is rated as an Elite provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Glioma, Astrocytoma, Glioblastoma, and Brain Tumor.

Mustafa Khasraw
Elite in Brain Tumor
Dr. Mustafa Khasraw
Oncology
Elite in Brain Tumor
Dr. Mustafa Khasraw
Oncology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
 (0.1 miles away)
919-681-6900
Languages Spoken:
English, Dutch
See accepted insurances
Accepting New Patients
Offers Telehealth

As a cancer doctor, I strive to provide the kind of care that I would want for my own family. My aim is to use my expertise, knowledge, and understanding of the human condition to empower patients. While scientific knowledge and approaches are at the core of what I do, I find it important to aim to integrate the human context into what my team and I offer patients and their families. Having lived, trained, and worked in different countries, including Australia, the United Kingdom, the Netherlands, and the United States, I have developed unique insights into the practice of medicine and cancer care around the world. These experiences have given me a broader perspective and helped inform my approach to individualized patient care. I see my ability to help patients as a privilege, and I do get enormous pleasure from being able to help. When not working, I am an avid reader and enjoy running, cycling, and spending time with my family. Dr. Khasraw is rated as an Elite provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Brain Tumor, and Hip Replacement.

Elite in Brain Tumor
Dr. Gordana V. Vlahovic
Oncology
Elite in Brain Tumor
Dr. Gordana V. Vlahovic
Oncology
40 Duke Medicine Cir, 
Durham, NC 
 (0.1 miles away)
919-684-8111
Languages Spoken:
English

Gordana Vlahovic is an Oncologist in Durham, North Carolina. Dr. Vlahovic is rated as an Elite provider by MediFind in the treatment of Brain Tumor. Her top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

VIEW MORE BRAIN TUMOR DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Anders's expertise for a condition
ConditionClose
  • Elite
  • Brain Tumor
    Dr. Anders is
    Elite
    . Learn about Brain Tumor.
    See more Brain Tumor experts
  • Breast Cancer
    Dr. Anders is
    Elite
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • HER-2 Positive Breast Cancer
    Dr. Anders is
    Elite
    . Learn about HER-2 Positive Breast Cancer.
    See more HER-2 Positive Breast Cancer experts
  • Metastatic Brain Tumor
    Dr. Anders is
    Elite
    . Learn about Metastatic Brain Tumor.
    See more Metastatic Brain Tumor experts
  • Triple-Negative Breast Cancer
    Dr. Anders is
    Elite
    . Learn about Triple-Negative Breast Cancer.
    See more Triple-Negative Breast Cancer experts
  • Distinguished
  • Angiosarcoma
    Dr. Anders is
    Distinguished
    . Learn about Angiosarcoma.
    See more Angiosarcoma experts
  • Inflammatory Breast Cancer
    Dr. Anders is
    Distinguished
    . Learn about Inflammatory Breast Cancer.
    See more Inflammatory Breast Cancer experts
  • Paget Disease of the Breast
    Dr. Anders is
    Distinguished
    . Learn about Paget Disease of the Breast.
    See more Paget Disease of the Breast experts
  • Advanced
  • Melanoma
    Dr. Anders is
    Advanced
    . Learn about Melanoma.
    See more Melanoma experts
  • Experienced
  • Glioma
    Dr. Anders is
    Experienced
    . Learn about Glioma.
    See more Glioma experts
  • Lung Cancer
    Dr. Anders is
    Experienced
    . Learn about Lung Cancer.
    See more Lung Cancer experts
  • Menopause
    Dr. Anders is
    Experienced
    . Learn about Menopause.
    See more Menopause experts
  • Non-Small Cell Lung Cancer (NSCLC)
    Dr. Anders is
    Experienced
    . Learn about Non-Small Cell Lung Cancer (NSCLC).
    See more Non-Small Cell Lung Cancer (NSCLC) experts
  • Posterior Fossa Tumor
    Dr. Anders is
    Experienced
    . Learn about Posterior Fossa Tumor.
    See more Posterior Fossa Tumor experts
  • Primitive Neuroectodermal Tumor (PNET)
    Dr. Anders is
    Experienced
    . Learn about Primitive Neuroectodermal Tumor (PNET).
    See more Primitive Neuroectodermal Tumor (PNET) experts
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.